TY - CONF A1 - Geißler, Daniel A1 - Resch-Genger, Ute T1 - Development of reference materials for flow cytometric analysis of extracellular vesicles N2 - The aim of task 1.4 within the EMPIR project 18HLT01 MetVesII is to produce low-RI solid particles with an effective RI between 1.37 and 1.42. To prepare these low-RI solid particles, polymer cores will be coated with a silica shell. Although the bulk RI of polymers, such as polystyrene (RI = 1.59) and PMMA (RI = 1.49), and fused silica (RI = 1.46) are higher than desired, an effective RI below 1.42 will be achieved by using a mesoporous silica shell with tuneable shell-thickness and a polymer core with sufficiently small size. This approach has four advantages: (1) monodisperse commercial polymer particles and silica shell chemistry are available, (2) low-RI solid particles will have a tuneable size and RI, (3) fluorescence can be added by incorporating fluorescent dyes into the polymer cores via an established staining procedure, and (4) fluorescent dyes within the polymer cores are shielded against influences from the sample matrix, e.g. fluorescence quenching effects altering the emission properties of the reference materials. T2 - MetVesII M9 Progress Meeting CY - Budapest, Hungary DA - 12.02.2020 KW - EMPIR 18HLT01 MetVesII KW - Extracellular vesicles (EV) KW - Flow cytometry (FCM) KW - Reference materials KW - Fluorescent particles PY - 2020 AN - OPUS4-50451 LA - eng AD - Bundesanstalt fuer Materialforschung und -pruefung (BAM), Berlin, Germany ER - TY - CONF A1 - Geißler, Daniel A1 - Resch-Genger, Ute T1 - Standardisation of concentration measurements of extracellular vesicles for medical diagnoses N2 - Extracellular vesicles (EVs) are cell-derived particles in body fluids, which have excellent potential as next generation biomarkers for the early diagnosis of common diseases, such as cancer and thrombosis. This project aims to tap into the clinical potential of EVs by developing traceable measurements of number concentration, size distribution, refractive index (RI) and fluorescence intensity of cell-specific EVs in human blood and urine. To realise our aims, we will develop synthetic reference materials with physical properties resembling EVs (WP1), instrumentation and procedures to standardise EV measurements in clinical laboratories (WP2), and ready-to-use biological test samples (WP3). These will then be evaluated in an inter-laboratory comparison study across a range (>20) of standard flow cytometers in clinical labs (WP4). T2 - MetVesII M18 Interim Meeting CY - Berlin, Germany DA - 20.10.2020 KW - EMPIR 18HLT01 MetVesII KW - Extracellular vesicles (EV) KW - Flow cytometry (FCM) KW - Reference materials KW - Fluorescent particles KW - Integrating sphere spectroscopy PY - 2020 AN - OPUS4-51653 LA - eng AD - Bundesanstalt fuer Materialforschung und -pruefung (BAM), Berlin, Germany ER -